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nosed with systemic fungal infections. METHODS:
Using the Cerner/Protocare Sciences hospital database
(01/00–03/01), patients with claims for either a systemic
fungal diagnosis (DX), oral/IV antifungal prescription
(RX), or both (DX/RX) were selected for evaluation 
of outcomes including mortality, length of stay (LOS),
and total hospital charges. Common comorbid conditions
were compared among these groups. RESULTS: Overall,
there were 492 cases of systemic fungal infections diag-
nosed in 451 patients. Urogenital candidiasis accounted
for the majority of encounters (range: 28% for DX/RX
to 40% for DX), followed by aspergillosis (14% for DX
to 25% for DX/RX) and disseminated candidiasis (2%
for DX to 25% for DX/RX). The most common prin-
cipal diagnoses were chemotherapy (3.5%) and acute
myeloid leukemia (2.6%). Microbiology was assessed in
1,253 encounters, of which 37% reported an isolate with
Candida albicans being most common (57%). A systemic
antifungal agent was prescribed in 69% of diagnosed
cases and in another 3421 episodes not accompanied by
a diagnosis code. Of the 3761 antifungal prescriptions,
oral ﬂuconazole was most commonly initiated (58%) 
followed by intravenous ﬂuconazole (22%) and conven-
tional amphotericin (9%). Mortality, average LOS and
median charges per encounter were: 4%, 9 days, $12,696
for the DX group; 14%, 26 days, $43,632 for RX group;
and 22%, 25 days, $43,207 for the DX/RX group,
respectively. There were no substantial differences in age
between comparator groups; however, the DX group had
more females (range: 49% for DX/RX to 67% female for
DX) and signiﬁcantly fewer comorbidities and high-risk
procedures performed. The most common comorbidities/
procedures of interest were concomitant antibiotic use
(93%), intravascular devices (21.7%) and bacteremia/
septicemia (17.7%). CONCLUSIONS: This study
demonstrates the signiﬁcant morbidity, mortality, and
economic burden associated with systemic fungal 
infections.
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OBJECTIVE: To describe the length of stay, the drug
treatment costs and the diagnosis and therapeutic tests
costs in patients hospitalized with a serious fungal infec-
tion and to analyze the factors associated to them.
METHODS: A retrospective review of the clinical records
of 399 hospitalization episodes which included a diag-
nosis of systemic mycosis going into 17 Spanish hospi-
tals have been performed. The length of stay has 
been described as global and by the type of pathogen
(aspergillosis, candidemia, emphirical and other
pathogens), drug treatment costs and diagnosis tests. A
descriptive analysis of the costs is performed. RESULTS:
The average length of stay of the patients under study was
38,87 days. The average length of the antifungal treat-
ment was 19,93 days, with 15,42 for intravenous treat-
ment and 4,49 days for oral therapy. Candidemia
represented the 42,6% of the sample, 17,3% was for
aspergillosis, 34,1% for empiric treatment, and the
resting 6% for other fungal infections. Amphotericin B
was prescribed in 11,6% of the patients (with or without
adding azoles), Amphotericin B lipid complex in 16,8%,
Amphotericin B lisosomal in 23,6%, and exclusively
Azoles in 29,3%. 9,2% of episodes were treated with a
combination of conventional amphotericin B with the
lipid or liposomal formulation, and a 3,8% a combina-
tion of these last two. Average cost of antifungal therapy
was €4.240,39 (€2.838,87 to €5.641,91), with a wide
variety between hospitals, determined by the type of anti-
fungals prescribed. People aged over 65 years old (and
occasionally people under 16 years old) showed shorter
average days of total treatment, intravenous and oral.
Transplanted and immunocompromised patients showed
a longer time of treatment, and those with previous cor-
ticotherapy showed longer stays. CONCLUSIONS: The
cost of hospital antifungal therapy is high and it is deter-
mined by the type of antifungal selected. Clinical charac-
teristics of patients may inﬂuence the total cost of the
treatment and/or the length of stay.
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OBJECTIVE: A pharmacoeconomic analysis was carried
out comparing the efﬁcacy of two treatment options for
community acquired pneumonia (CAP): Telithromycin
and Clarithromycin. METHODS: Retrospective analysis
using a decision tree model. The efﬁcacy of the two treat-
ment options was estimated from a randomised, double-
blind clinical trial, in which 800mg/day of Telithromycin
was compared to 1,000mg/day of Clarithromycin in
patients with CAP (162 and 156 respectively). The utili-
sation of resources was captured in the clinical trial with
estimated Spanish sources, and the unit costs from a
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Spanish health costs database. Costs were evaluated for
the acquisition of antibiotic treatments, change of anti-
biotic due to therapeutic failure, hospital admissions,
adverse reactions treatment, primary care visits, tests and
indirect costs (working days lost). The model was vali-
dated by a panel of Spanish clinical experts. RESULTS:
As there were no signiﬁcant differences in efﬁcacy be-
tween the treatment options (clinical cure rate 88.3% and
88.5% respectively), a cost minimisation analysis was
performed. In the base case, the average cost of the
disease per patient was €308.29 with Telithromycin and
€331.5 with Clarithromycin (a difference of €23.21). The
results were stable in the sensitivity analysis, with differ-
ences favourable to Telithromycin ranging between €5.50
and €45.45. CONCLUSIONS: Telithromycin results in a
cost saving of up to €45.45 per patient with CAP com-
pared to Clarithromycin.
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OBJECTIVE: A cost-effectiveness analysis was con-
ducted, from the perspective of the Spanish National
Healthcare System, comparing sequential IV/PO moxi-
ﬂoxacin (MXF) monotherapy to standard comparators in
patients with CAP. METHODS: Costs and consequences
over 21 days were evaluated based on clinical cure rates
5–7 days post-treatment (test-of-cure (TOC) visit) and
resource use reported for the TARGET multinational,
randomized, open-label trial. Sequential IV/PO
monotherapy with MXF 400mg OD was compared to
IV/PO amoxicillin/clavulanate (AMC) (1.2g IV/625mg
PO TID) +/- clarithromycin (CLA) (500mg BID) for 7–14
days in hospitalized patients with CAP. Since the treat-
ment effect on resource use was similar across countries,
resource data from all centers were pooled and valued
using Spanish unit prices to estimate CAP-related
cost/patient to the Spanish healthcare system. RESULTS:
Clinical efﬁcacy analyses for the ITT and PP populations
found 8.3% (95% CI: 3.1, 13.6) and 8.1% (95% CI: 2.9,
13.2) higher cure rates in the MXF group at TOC. For
the economic evaluation, patients with an indeterminate
or missing outcome at TOC were assumed to be clinical
failures, resulting in higher cure rates in the MXF group
of 5.3% (95% CI 1.2%, 11.8%). A statistically signiﬁ-
cant increased speed of response (ﬁrst return to apyrexia
1 day sooner; p = 0.008) and reduction in hospital stay
by 0.81 days (95% CI: 1.63, 0.01) was observed in the
MXF group. Treatment with MXF resulted in savings of
€254/patient to the Spanish healthcare system, primarily
due to a shorter hospital stay. A cost-effectiveness accept-
ability curve demonstrated the probability of MXF being
cost saving was 90%, and the probability of MXF being
cost-effective relative to AMC ± CLA reached 94% at
acceptability thresholds up to €2000/additional patient
cured. CONCLUSION: MXF IV/PO monotherapy shows
signiﬁcant clinical outcomes and is cost-effective to the
Spanish National Healthcare System compared to IV/PO
AMC ± CLA in the treatment of CAP.
PIN11
COMPARING HOSPITAL COSTS BETWEEN
LINEZOLID AND VANCOMYCIN IN THE
TREATMENT OF METHICILLIN-RESISTANT
STAPHYLOCOCCAL SPECIES (MRSS)
INFECTIONS:A RANDOMIZED MULTI-CENTER
CLINICAL TRIAL
Glick HA1, Willke RJ2, Rittenhouse BE2, Balan DA3,
Orzol SM1, Li JZ4
1University of Pennsylvania, Philadelphia, PA, USA; 2Pharmacia,
Peapack, NJ, USA; 3Western Michigan University, Kalamazoo,
MI, USA; 4Pharmacia Corp, Kalamazoo, MI, USA
OBJECTIVES: In a Phase-3 clinical trial we compared
hospital and outpatient antibiotic treatment costs for
MRSS patients treated with linezolid to those treated with
vancomycin. Linezolid, ﬁrst of a new class of antibiotics,
the oxazolidinones, is active against gram positive bacte-
ria sensitive and resistant to other antibiotics and is avail-
able in bioequivalent oral and IV formulations. Hospital
length of stay data from this trial (Li et al, 2001), sug-
gests linezolid use may result in earlier discharge than
vancomycin use. METHODS: Hospitalized patients with
pneumonia, skin/soft tissue infection, right-sided endo-
carditis, urinary tract infection, or bacteremia caused by
MRSS were treated with linezolid (IV/oral, n = 240) or
vancomycin (IV only, n = 220) in a randomized multi-
center clinical trial. Of the 460 intent-to-treat (ITT)
patients, 254 were clinically evaluable. Patients received
up to four weeks of treatment followed by up to four
weeks of post-treatment observation, including outpa-
tient use of study medication. Total hospital costs were
calculated using observed resource use (inpatient days by
hospital unit type, non-investigational therapies and 
medications, and study medications) and 1999 unit costs
from 8 countries, adjusted to 2001 price levels. Using a
societal perspective, total costs are compared using mean,
median and regression-adjusted (linear and log) differ-
ences. RESULTS: Mean and median total costs in the ITT
sample were higher for linezolid patients than van-
comycin patients, but no differences were statistically dif-
ferent from zero. Non-normality caused unadjusted mean
